Australian Consumer Services Stock News

ASX:EOS
ASX:EOSAerospace & Defense

Electro Optic Systems (ASX:EOS) Is Up 19.5% After Funding MARSS Deal And Defence Board Refresh – What's Changed

Electro Optic Systems Holdings has recently raised A$150,000,000 via an institutional placement, A$40,000,000 through a follow-on offering, and plans an additional A$25,000,000 Share Purchase Plan to help fund the acquisition of UK counter-drone and autonomous maritime specialist MARSS, while also adding retired senior Australian Defence leaders Catherine Roberts and Kathryn Toohey to its board. This combination of sizeable equity raising, a defence-focused acquisition, and governance...
ASX:GMG
ASX:GMGIndustrial REITs

Goodman Group (ASX:GMG) Valuation Check After New Sagamihara Data Centre Partnership

Goodman Group (ASX:GMG) has been appointed lead development partner for a proposed data centre campus in Sagamihara City, Kanagawa Prefecture, Japan, highlighting its growing role in digital infrastructure and sustainability focused projects. See our latest analysis for Goodman Group. The Sagamihara announcement comes as Goodman Group trades at A$30.77, with a 30 day share price return of 6.47% and a 90 day share price return of 6.32%. The 3 year total shareholder return of 60.30% contrasts...
ASX:NUF
ASX:NUFChemicals

Nufarm (ASX:NUF) H1 Profit Of A$28m Tests Long Running Loss Concerns

Nufarm (ASX:NUF) opened H1 2026 with revenue of A$1.7 billion and basic EPS of A$0.07, alongside net income of A$28.0 million. Over the recent half yearly periods, the company has seen revenue move from A$1.8 billion and EPS of A$0.05 in H1 2025 to A$1.6 billion with EPS declining to A$0.54 in H2 2025, before landing at the latest H1 2026 levels. This gives investors a clearer read on how margins are tracking quarter to quarter. Against a backdrop of trailing twelve month losses and analyst...
ASX:SGLLV
ASX:SGLLVFood

3 Dividend Fortresses With High Yields And Underpriced Earnings Power

Income investors are being pulled in several directions by stubborn inflation signals, shifting rate expectations and uneven consumer data across major economies. In this kind of cross‑current, high yield alone is not enough; durability matters just as much as payout. That is exactly what the Dividend Fortresses screener is built to target, focusing on stocks with dividend yields of 5% or more that aim to hold up when conditions get choppy. In this article, you will see three stocks from that...
ASX:SHV
ASX:SHVFood

Select Harvests H1 2026 Margin Slippage Tests Bullish Earnings Narratives

Fresh from its H1 2026 update, Select Harvests (ASX:SHV) is under the spotlight as you weigh recent revenue and EPS trends against the stock’s A$3.90 share price and what they might signal for profitability. The company has seen half year revenue shift from A$226.4 million in H2 2024 to A$293.8 million in H2 2025, while basic EPS over the same periods moved from A$0.03 to A$0.02, setting up a mixed read on earnings momentum. With trailing 12 month net profit margin at 8.4% versus 8.7% in the...
ASX:GDG
ASX:GDGInsurance

ASX Penny Stocks With Market Caps Under A$3B To Consider

Australian shares are poised for a slight retreat, influenced by Wall Street's recent cooling and ongoing global economic discussions. Despite the fluctuating market conditions, penny stocks—often overlooked due to their smaller size or newer status—can still present valuable opportunities when backed by solid financials. In this article, we explore several promising Australian penny stocks that combine financial strength with potential for long-term growth.
ASX:TLX
ASX:TLXBiotechs

How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) Glioblastoma Trial Enrolment Milestone

Earlier in May 2026, Telix Pharmaceuticals reported that its Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma completed enrolment, with no dose-limiting toxicities observed so far at doses up to 10GBq alongside standard-of-care therapy. This progress, together with ongoing Phase 3 evaluation of TLX101-Tx as the first radiopharmaceutical therapy to reach this stage in glioblastoma, highlights Telix’s attempt to build a differentiated neuro-oncology franchise using...
ASX:LYC
ASX:LYCMetals and Mining

Low Risk Leaders Quietly Powering Gold And Rare Earths

Markets are being pulled in different directions by geopolitics, energy prices and shifting interest rate expectations, and it can feel hard to know where to focus. One approach is to build around companies that aim to be resilient when conditions change. Our Low-Risk Leaders screener targets stocks with strong balance sheets and low model risk scores, designed to help reduce volatility while still keeping you in the market. In this article, you will see three stocks from that screener and...
ASX:BTL
ASX:BTLOil and Gas

ASX Growth Companies With High Insider Ownership To Watch

As the Australian market holds steady, awaiting key inflation data amid global volatility in oil prices and mixed signals from international markets, investors are keenly observing sectors that promise growth potential. In this context, companies with high insider ownership can offer unique insights into future performance, as insiders who have significant stakes often align their interests closely with those of other shareholders.
ASX:CAT
ASX:CATSoftware

3 ASX Stocks Estimated To Be Trading Below Intrinsic Value By Up To 48.7%

As the Australian market holds steady, awaiting key economic data like the anticipated April inflation print, investors are keenly observing how these developments might impact stock valuations. In this environment, identifying stocks trading below their intrinsic value can present opportunities for those looking to capitalize on potential market inefficiencies.
ASX:EHL
ASX:EHLTrade Distributors

Undiscovered Gems in Australia for May 2026

As the Australian market holds steady, awaiting key inflation data, the broader sentiment remains cautious amid global economic shifts and volatile commodity prices. In this environment, identifying promising small-cap stocks requires a keen eye for potential growth drivers and resilience in challenging conditions.
ASX:ARX
ASX:ARXBiotechs

ASX Penny Stocks Spotlight Aroa Biosurgery And Two More Top Picks

As the Australian market holds steady, waiting for crucial inflation data, investors are keeping a close eye on potential opportunities amidst global economic shifts. Penny stocks, a term that may seem outdated but remains relevant, represent smaller or newer companies with potential for growth and value. By focusing on those with strong financials and clear growth trajectories, investors can uncover promising opportunities in this unique segment of the market.
ASX:PME
ASX:PMEHealthcare Services

Assessing Pro Medicus (ASX:PME) Valuation After Long‑Serving Finance Executive Announces Resignation

Pro Medicus (ASX:PME) has drawn fresh attention after announcing the planned resignation of Clayton Hatch, Head of Business Operations and Investor Relations, who previously served as long-time Chief Financial Officer. See our latest analysis for Pro Medicus. The executive change comes as Pro Medicus trades at A$130.6, with the share price up 2.6% over the past day and 1.5% over the week but down 41.3% year to date. The 1 year total shareholder return has declined 53.5%, while longer term 3...
ASX:WOR
ASX:WORConstruction

Is Worley (ASX:WOR) Priced Fairly After Recent Contract Pipeline Updates?

Wondering if Worley at A$12.94 is offering fair value or if the price is getting ahead of itself? This article explains what the current share price might be indicating. Over the past week the stock has returned 6.5%, with 9.5% over the last month and 3.1% year to date, while the 1 year return is 3.5% and the 3 year return shows a decline of 12.0% compared to a 38.3% gain over 5 years. Recent news flow around Worley has focused on its role as an engineering and consulting provider to energy...
ASX:ALQ
ASX:ALQProfessional Services

How Investors Are Reacting To ALS (ASX:ALQ) Earnings And Its Strict 15% ROCE Deal Filter

ALS Limited (ASX:ALQ) recently reported full-year results to March 31, 2026, with revenue of A$3,320.1 million and net income of A$318.7 million, alongside reaffirmed focus on acquisitions that meet strict return hurdles. Management’s insistence on only pursuing bolt-on deals that can reach a 15% return on capital employed by year five offers insight into how ALS balances growth ambitions with disciplined capital allocation. We’ll now explore how this earnings performance and disciplined 15%...